Infusion Drug Delivery Videos

31. Solving Formulation Challenges Across Modalities 6/15/2026

    Optimize drug delivery by leveraging advanced nanoparticle engineering to dramatically increase small-molecule oral drug loading and enable ultra-high-concentration subcutaneous formulations.

32. How Formulation Scientists View Drug Delivery With Yogesh Bachhav 9/28/2026

    Videocast host Tom von Gunden talks with Yogeshwar Bachhav, CMC consultant for AiCuris AG Germany, about scientific and technical considerations in the alignment of drug formulations with routes of administration and related delivery systems during product development. Topic coverage includes delivery considerations related to viscosity, permeability, solubility, safety, usability, packaging, and supply chain.

33. Deploying Immunologic Viral Agents To Target Cancers With Oncolytics Biotech's Thomas Heineman 2/27/2025

    In this episode of Sit and Deliver, host Tom von Gunden talks with Oncolytics Biotech’s Chief Medical Officer Thomas Heineman about deploying oncolytic viral agents to ensure successful arrival at lymph nodes and at primary and metastatic tumor sites.

34. 3 Key 'Look Forwards' In Drug Delivery Regulatory 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden invites panelists Fran DeGrazio, Barr Weiner, and Rumi Young to identify and comment on their most important takeaways from their panel conversation. They point to platform thinking, post-market manufacturing, and the representation of combination products in regulatory guidances.

35. URRA And UFMEA: Together Or Separate For Combination Products? 12/11/2024

    Both uFMEA (Use Failure Mode Effects Analysis) and URRA (Use-Related Risk Analysis) tools are available during combination product development for conducting risk assessments related to human factors. In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, and Shannon Hoste, chief scientific officer at Pathway for Patient Health, discuss scenarios in which a uFMEA might be used to inform a URRA regulatory submission.

36. Clarifying The EDDO Focus On Design Outputs, Not Design Inputs 10/9/2024

    In what ways are Essential Drug Delivery Outputs (EDDOs) different from design inputs for combination products? In this segment of the Drug Delivery Leader Live event The FDA Guidance on EDDO: What to Know, What to Do, consultant Susan Neadle of Combination Products Consulting Services, LLC explains the difference.

37. Identifying EDDOs During Drug Delivery Device Design 10/9/2024

    How are EDDOs (Essential Drug Delivery Outputs) determined during the design of a drug-led or biologic-led combination product? In this segment of the Drug Delivery Leader Live event The FDA Guidance on EDDO: What to Know, What to Do, consultant Susan Neadle of Combination Products Consulting Services, LLC lays out the foundational considerations.

38. An EDDO Identification Tutorial For A Prefilled Syringe (PFS) 4/23/2025

    In this segment of the Drug Delivery Leader Live event EDDOs Revisited: Putting Essential Drug Delivery Outputs Into Practice, consultant Susan Neadle of Combination Products Consulting Services, LLC, and Alan Stevens, regulatory head of complex devices and drug delivery systems at AbbVie, use a hypothetical case study for a prefilled syringe (PFS) to demonstrate a template for identifying EDDOs.

39. Becoming A Combination Product Development Organization 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on regulatory challenges and considerations for traditional drug product pharma companies moving into combination product development. Patient centricity, device expertise, and supplier relationships are among the topics identified.

40. Leveraging Janus Base Nanoparticles For Precision Therapeutic Delivery With Eascra's Mari Anne Snow 10/31/2025

    A major challenge in delivering biologics-based therapies is penetrating cells for precision delivery to therapeutic targets. In this episode of Supplier Horizons, host Tom von Gunden and CEO Mari Anne Snow from platform technology developer Eascra Biotech discuss the use of Janus base nanoparticles to effectively and safely encapsulate therapeutic payloads, including CGTs and other large molecule biologics. The conversation also turns to the benefits of particle production conducted in space.